Showing results (111-120 of 242) with videos related to

Sort By:
Pageof 25
Gynecologic Oncology|June 11, 2021
Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer: Analysis of the VELIA/GOG-3005 trialCarol Aghajanian, Michael A Bookman, Gini F Fleming, et al.
Gynecologic Oncology|August 15, 2024
Are exercise and sitting time during chemotherapy for ovarian cancer associated with treatment-related side-effects, chemotherapy completion and survival?Tanya L Ross, Renhua Na, George Au-Yeung, et al.
Breast Cancer Research : BCR|October 29, 2003
Log odds of carrying an Ancestral Mutation in BRCA1 or BRCA2 for a Defined personal and family history in an Ashkenazi Jewish woman (LAMBDA)Carmel Apicella, Lesley Andrews, Shirley V Hodgson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2012
BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study GroupKathryn Alsop, Sian Fereday, Cliff Meldrum, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 25, 2014
Gynecologic Cancer Intergroup (GCIG) consensus review for ovarian germ cell tumorsJubilee Brown, Michael Friedlander, Floor J Backes, et al.
Scientific Reports|November 25, 2021
Corneal dendritic cells and the subbasal nerve plexus following neurotoxic treatment with oxaliplatin or paclitaxelJeremy Chung Bo Chiang, David Goldstein, Azadeh Tavakoli, et al.
Gynecologic Oncology|December 6, 2025
Evaluating patient perspectives about the acceptability of a novel prognostic gene expression signature for high grade serous ovarian cancer: The OTTA-SPOT studyHolly E Evans, Amber-Marie Firriolo, Rachel Houweling, et al.
JCO Precision Oncology|May 1, 2024
Plasma Lipidomic Profiling Identifies Elevated Triglycerides as Potential Risk Factor in Chemotherapy-Induced Peripheral NeuropathyNicole Yeung, Tiffany Li, Hui-Ming Lin, et al.
The Lancet. Oncology|February 2, 2015
Outcomes and endpoints in cancer trials: bridging the divideMichelle K Wilson, Deborah Collyar, Diana T Chingos, et al.
The Cochrane Database of Systematic Reviews|September 23, 2024
Predictive value of homologous recombination deficiency status for survival outcomes in primary tubo-ovarian high-grade serous carcinomaTibor A Zwimpfer, Hannah Ewald, Esra Bilir, et al.
Pageof 25